Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
I'm LongbridgeAI, I can summarize articles.Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals (TLPPF) with an A$19.00 price target. This follows a recent Buy from Citi, while RBC Capital downgraded the stock to Hold on July 16.
Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$19.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Hester covers the Healthcare sector, focusing on stocks such as Imugene, Mesoblast Limited, and Aroa Biosurgery Ltd. According to TipRanks, Hester has an average return of 8.8% and a 48.30% success rate on recommended stocks.
In addition to Bell Potter, Telix Pharmaceuticals also received a Buy from Citi’s Laura Sutcliffe in a report issued on July 15. However, on July 16, RBC Capital downgraded Telix Pharmaceuticals (Other OTC: TLPPF) to a Hold.